What is the appropriate regimen for prescribing progesterone vaginal gel to protect the endometrium in a woman receiving estrogen‑only hormone replacement therapy with an intact uterus?

Prescribing Progesterone Vaginal Gel for Endometrial Protection in HRT

For women with an intact uterus receiving estrogen-only hormone replacement therapy, vaginal micronized progesterone gel should be prescribed at 45 mg (4% gel) every other day for at least 10 days per month, or 100 mg every other day for 10-12 days per 28-day cycle, for up to 3-5 years. 1

Key Dosing Regimens

The evidence supports two primary approaches for vaginal progesterone gel:

Sequential Regimen (Preferred)

• Dose: 45 mg (4% gel) applied vaginally every other day, OR 100 mg every other day
• Duration: At least 10 days per month, preferably 12-14 days per 28-day cycle
• Maximum duration: Up to 3-5 years of documented safety 2
• Timing: Applied cyclically with continuous estrogen therapy

Important Mechanistic Consideration

Vaginal progesterone achieves endometrial protection through a unique "first-pass uterine effect." Despite producing lower serum progesterone levels compared to oral or intramuscular routes, vaginal administration delivers significantly higher progesterone concentrations directly to endometrial tissue 3. This explains why lower systemic doses can provide adequate endometrial protection while minimizing systemic side effects.

Evidence Quality and Limitations

Supporting Evidence

• Studies demonstrate secretory endometrial transformation in 35 of 41 adequate tissue samples with vaginal progesterone gel 4
• Plasma progesterone concentrations of 4.6-6.8 ng/mL achieved with 45-90 mg doses provide endometrial protection 4
• One case of proliferative endometrium with 45 mg dose, zero cases of hyperplasia documented 4

Critical Caveat: Off-Label Use

This is off-label prescribing. The FDA-approved indication for oral micronized progesterone capsules specifies 200 mg daily for 12 continuous days per 28-day cycle for endometrial protection 5. Vaginal administration, while supported by clinical evidence, is not FDA-approved for this indication 6.

Comparison to Standard Oral Therapy

FDA-Approved Oral Regimen

• Dose: 200 mg micronized progesterone capsules
• Duration: 12 continuous days per 28-day cycle
• Route: Oral, taken at bedtime
• Duration of use: Up to 5 years documented safety 5, 2

Why Consider Vaginal Route?

• Fewer systemic side effects: Reduced drowsiness, dizziness, mood changes 6
• Better tolerability: Women intolerant to oral progestogens may tolerate vaginal administration 6
• Functional endometrium: More frequently induces secretory-like endometrium versus atrophic changes seen with oral synthetic progestogens 7

Monitoring Requirements

Any abnormal vaginal bleeding requires immediate endometrial evaluation 8, 6. This includes:

• Bleeding between progestogen exposure periods
• Unexpected bleeding patterns on any regimen
• Perform transvaginal ultrasound and endometrial biopsy with low threshold 6

Alternative Progestogen Options

If vaginal progesterone is not suitable or desired:

Oral Micronized Progesterone (First Choice)

• 200 mg daily for 12-14 days per month 1, 6
• Associated with lower cardiovascular and thrombotic risk compared to synthetic progestogens 1

Other Oral Progestogens

• Medroxyprogesterone acetate: 10 mg for 10-12 days/month 6
• Dydrogesterone: 10 mg for 12-14 days/month 1
• Norethindrone acetate: 5 mg for 10-12 days/month 6

Transdermal Options

• Combined estradiol-progestogen patches available 6
• Note: Transdermal micronized progesterone alone does NOT provide endometrial protection 2

Critical Warnings

Absolute Contraindications to Vaginal Progesterone

• Peanut allergy (if formulation contains peanut oil) 5
• Unusual vaginal bleeding (requires evaluation first) 5
• Current or history of breast cancer, endometrial cancer 5
• Active thromboembolism or cardiovascular disease 5

Duration Considerations

Progestogen therapy must continue for the entire duration of estrogen therapy 8. Unopposed estrogen dramatically increases endometrial cancer risk (Grade A evidence) 8. The minimum protective duration is 10 days per month, but 12-14 days provides more reliable protection 8.

Long-Cycle Regimens: Use with Caution

Some guidelines mention progestogen for 14 days every 3 months to reduce breast exposure 8, but this approach lacks definitive validation for endometrial protection and may increase endometrial cancer risk 9. This should not be routinely recommended.

Practical Prescribing Algorithm

1. Confirm intact uterus and need for endometrial protection
2. Screen for contraindications (especially peanut allergy if using oil-based formulations)
3. Choose regimen:
   • First-line: Oral micronized progesterone 200 mg for 12 days/month (FDA-approved)
   • Alternative: Vaginal progesterone gel 45-100 mg every other day for 10-12 days/month (off-label, better tolerated)
4. Counsel patient on expected withdrawal bleeding with sequential regimens
5. Monitor annually with pelvic exam; investigate any abnormal bleeding immediately
6. Reassess benefit-risk annually and consider discontinuation after 5 years or at average menopause age (50-55 years) 1